Survodutide vs Tirzepatide vs Retatrutide: Next-Gen Weight Loss Drugs Compared

Semaglutide proved that GLP-1 receptor agonists could produce meaningful weight loss — 15-17% on average. But the next generation of obesity drugs pushes further by targeting multiple hormone receptors simultaneously, a strategy called multi-agonism.

Three compounds represent the leading edge: tirzepatide (dual GLP-1/GIP agonist, FDA-approved), survodutide (dual GLP-1/glucagon agonist, Phase 3), and retatrutide (triple GLP-1/GIP/glucagon agonist, Phase 3). Each activates a different combination of metabolic hormone receptors, and each has distinct clinical advantages.

The obesity treatment landscape is moving from a one-size-fits-all model toward a personalized approach where the choice of drug depends on a patient's metabolic profile, comorbidities, and treatment goals.

All three share GLP-1 receptor agonism as a common foundation but differ in additional receptor targets, creating meaningfully different metabolic effects.

Tirzepatide: GLP-1 + GIP dual agonist. Tirzepatide activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. GIP agonism at pharmacological doses complements GLP-1 by enhancing insulin sensitivity, improving lipid metabolism, and possibly amplifying central appetite suppression. FDA-approved as Mounjaro (diabetes) and Zepbound (obesity).

Survodutide: GLP-1 + glucagon dual agonist. Survodutide activates GLP-1 and glucagon receptors. Glucagon increases hepatic fat oxidation, raises energy expenditure through thermogenesis, and promotes amino acid catabolism. The major advantage is its direct action on the liver via glucagon receptors highly expressed in hepatocytes — making survodutide the most liver-targeted of the three. Developed by Boehringer Ingelheim, currently in Phase 3.

Retatrutide: GLP-1 + GIP + glucagon triple agonist. Retatrutide combines all three receptor targets in a single molecule. This maximalist approach aims to capture the benefits of both tirzepatide-like GIP agonism and survodutide-like glucagon agonism. Eli Lilly is developing retatrutide, and the triple approach has produced the highest weight loss numbers in trials. Whether the additional complexity translates to proportionally better outcomes is the central question.

Comparing weight loss requires careful attention to trial design — Phase 2 and Phase 3 results are not directly comparable.

Tirzepatide: ~22.5% weight loss (Phase 3, 72 weeks). The SURMOUNT-1 trial demonstrated 22.5% mean body weight reduction at the highest dose (15 mg) over 72 weeks. This is the most robust data from the largest and longest trial, and the benchmark for the others.

Retatrutide: ~24% weight loss (Phase 2, 48 weeks). The Phase 2 trial in the New England Journal of Medicine showed approximately 24% weight loss at the highest dose (12 mg) over 48 weeks — the highest for any obesity drug. However, Phase 2 trials enroll smaller, more selected populations, and results do not always replicate in Phase 3.

Survodutide: ~19% weight loss (Phase 2, 46 weeks). The Phase 2 ACHIEVE trial showed approximately 19.1% at the highest dose (6 mg). While impressive, this is lower than both tirzepatide's Phase 3 and retatrutide's Phase 2 numbers. Survodutide's value proposition lies in liver outcomes rather than maximum weight loss.

Important caveats. These numbers cannot be directly compared across trials. Differences in patient populations, duration, dose titration, and inclusion criteria all affect outcomes. Only a head-to-head trial could definitively rank these drugs. Phase 3 data for survodutide and retatrutide (expected 2027) will provide more reliable comparisons.

Each drug's multi-agonist profile produces distinct metabolic benefits that may matter more for specific patient populations than raw weight loss numbers.

Tirzepatide — broadest evidence base. Beyond weight loss, tirzepatide has demonstrated superior glycemic control (SURPASS trials), dramatic sleep apnea improvement (SURMOUNT-OSA), heart failure benefit (SUMMIT trial), and broad metabolic improvements including triglycerides, HDL cholesterol, and blood pressure. Its advantage is the most extensive clinical evidence across the widest range of conditions.

Survodutide — strongest liver disease signal. Survodutide's glucagon component gives it a direct mechanism for reducing liver fat. Phase 2 data showed 45-50% liver fat reduction, 64% ALT reduction, and 48% fibrosis improvement in MASH patients. If Phase 3 confirms these results, survodutide could become the preferred drug for the estimated 6-8 million Americans with MASH and obesity. This liver-targeting profile is its key differentiator.

Retatrutide — most comprehensive metabolic coverage. Retatrutide's triple agonism provides the broadest metabolic profile. Phase 2 data showed robust improvements across glycemic control, lipid parameters, liver fat, and blood pressure. The inclusion of both GIP and glucagon agonism means retatrutide may address the widest range of metabolic abnormalities in a single drug.

All three share GI side effects common to GLP-1 drugs, but additional receptor targets introduce distinct considerations.

GI tolerability. Nausea, vomiting, and diarrhea occur with all three at rates of 20-40%, typically highest at treatment initiation and decreasing over time. Dose titration mitigates these effects. No strong evidence indicates one drug has clearly better GI tolerability, though retatrutide's triple mechanism may theoretically produce higher rates.

Glucose effects. Survodutide and retatrutide's glucagon agonism could theoretically cause hyperglycemia, but clinical data shows adequate glucose control maintained by the GLP-1 component. Tirzepatide's GIP component enhances insulin sensitivity, making it the most reliably glucose-lowering — an advantage in type 2 diabetes patients.

Cardiovascular data. Long-term cardiovascular outcome data exists only for semaglutide (favorable) and is being generated for tirzepatide. No cardiovascular outcome data exists for survodutide or retatrutide yet.

Muscle mass preservation. Limited data suggests tirzepatide may preserve lean mass better than pure GLP-1 agonists, possibly due to GIP's effects on bone and muscle. Comparative data for the other two is insufficient.

The three drugs are at very different development stages — a critical practical consideration.

Tirzepatide — available now. FDA-approved and commercially available as Mounjaro (diabetes) and Zepbound (obesity). Supply constraints have largely resolved. Cost remains approximately $1,000/month without insurance.

Survodutide — Phase 3, potential approval 2028-2029. Phase 3 trials (SYNCHRONIZE-NASH and SYNCHRONIZE-OBESITY) have results expected in 2027. If positive, approval could come in 2028-2029.

Retatrutide — Phase 3, potential approval 2028-2029. Also in Phase 3 development by Eli Lilly with a similar timeline. Lilly's commercial strategy for retatrutide alongside existing tirzepatide is an important unknown.

There is no single "best" drug — the optimal choice depends on clinical profile and treatment goals.

Choose tirzepatide if you need treatment now (only one available), have type 2 diabetes alongside obesity (strongest glycemic data), have sleep apnea (SURMOUNT-OSA data), or prefer a drug with the most extensive evidence base.

Consider survodutide if you have MASH or significant fatty liver disease (strongest liver data), your primary goal is liver health improvement alongside weight loss, and Phase 3 confirms Phase 2 benefits. Available 2028-2029.

Consider retatrutide if you seek maximum weight loss (highest Phase 2 numbers), want the broadest metabolic coverage, and Phase 3 confirms efficacy without significant safety concerns. Available 2028-2029.

The bigger picture. Three distinct multi-agonist approaches represent a maturation of the GLP-1 class from a single mechanism to a family of specialized agents. This is positive for patients — more options mean better matching of drug to individual needs. The next 2-3 years of Phase 3 data will determine which approaches deliver on their promise.